Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of LYL845 in Advanced Solid Tumors
NCT05573035Phase 1Terminated
- Sponsor
- Lyell Immunopharma
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LYL845 in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Lyell Immunopharma. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Incidence of Treatment-Emergent Adverse Events at 2 years and 2 more. Started Dec 2022; status: terminated.
02
Drugs
LYL845
03
Conditions
melanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05573035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573035.